Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data [Seeking Alpha]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Seeking Alpha
Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival. Ongoing Phase 2 trials for Onvansertib in various cancers include collaborations with Pfizer and other prestigious institutions. The company is a biotech microcap with a cash runway extending to Q3 2025 and promising upcoming catalysts in 1H 2024. I deem CRDF a “speculative buy” due to Onvansertib's promising early data and market potential despite the inherent biotech risks. Cardiff Oncology, Inc. ( NASDAQ: CRDF ) is a San Diego-based clinical-stage biotech focusing on developing innovative cancer treatments. CRDF's leading drug candidate, Onvansertib, is a first-in-class oral Polo-like Kinase 1 [PLK1] inhibitor that interferes with cancer cell division and may hinder cancer growth. Onvansertib is Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology to Present at the Jefferies Healthcare ConferenceGlobeNewswire
- Cardiff Oncology to Present at Upcoming Investor Conferences in MayGlobeNewswire
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 5/2/24 - Beat
CRDF
Analyst Actions
- 5/6/24 - HC Wainwright
CRDF
Sec Filings
- 6/20/24 - Form 8-K
- 6/17/24 - Form DEFA14A
- 6/3/24 - Form DEFA14A
- CRDF's page on the SEC website